Ambrx Biopharma Return on Investment 2020-2022 | AMAM
Current and historical return on investment (ROI) values for Ambrx Biopharma (AMAM) over the last 10 years.
| Ambrx Biopharma ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.335B | $0.007B |
| Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $140.576B | 8.70 |
| GSK (GSK) | United Kingdom | $75.923B | 9.52 |
| Bio-Rad Laboratories (BIO.B) | United States | $13.735B | 32.61 |
| QIAGEN (QGEN) | Netherlands | $10.436B | 19.34 |
| Ginkgo Bioworks Holdings (DNA) | United States | $2.549B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.194B | 0.00 |
| Biohaven (BHVN) | United States | $0.913B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $0.394B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.152B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.106B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.024B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.012B | 0.00 |
